PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025
|
EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Forecast/Change in Forecast Publication of inside information in accordance with Article 17 of Regulation (EU) No. 596/2014 PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025 Gräfelfing, July 11, 2025 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has today decided, based on an evaluation of current data on business development completed today, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. Adjusted EBITDA is still expected to be between €37.0 million and €39.0 million, which, taking into account the adjusted revenues forecast, corresponds to an adjusted EBITDA margin of 26.8% to 29.5%. The previous forecast implied an adjusted EBITDA margin of 28.9% to 32.0%. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time. The preliminary figures for the first half of 2025 will be published as planned on September 11, 2025. The half-year financial report will be published on September 25, 2025. Note: Adjusted EBITDA is not a measure in accordance with IFRS. Information on the adjustments used to derive adjusted EBITDA is available in the 2024 Annual Report of PharmaSGP Holding SE on page 70 (available at https://ir.pharmasgp.com).
CONTACT cometis AG
ABOUT PHARMASGP HOLDING SE PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects. The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%. In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
End of Inside Information
11-Jul-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2168340 |
| End of Announcement | EQS News Service |
|
|
2168340 11-Jul-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.